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National Lung Hospital, Hanoi, VietnamAbstractMultidrug-resistant tuberculosis is a major issue worldwide; however, accessibility to drug susceptibility testing (DST) is still limited in
developing countries, owing to high costs and complexity. We developed a proportion method on 12-well microplates for DST. The
assay reduced the time to results to <12 days and <10 days when bacterial growth was checked with the naked eye or a microscope,
respectively. Comparison with the Canetti–Grosset method showed that the results of the two assays almost overlapped (kappa index
0.98 (95% CI 0.91–1.00) for isoniazid, rifampicin, streptomycin; and kappa index 0.92 (95% CI 0.85–0.99) for ethambutol). The
sequencing of genes involved in drug resistance showed similar level of phenotype–genotype agreement between techniques. Finally,
measurement of the MICs of rifampicin and ethambutol suggests that the currently used critical ethambutol concentration should be
revised, and that the current molecular drug susceptibility tests for rifampicin need to be re-evaluated, as in vitro rifampicin-sensitive
isolates could harbour drug resistance-associated mutation(s).
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E-mails: vananhtdt@gmail.com, vananh@nihe.org.vnIntroductionMultidrug-resistant tuberculosis (MDR-TB), i.e. tuberculosis
(TB) resistant to at least isoniazid and rifampicin, the two
essential ﬁrst-line anti-TB drugs [1]), is a major challenge.
However, in the countries with the highest MDR-TB burden,
less than one-ﬁfth of patients with MDR-TB are detected, owing
to the lack of diagnostic capacity [2], leading to treatments
without prior drug susceptibility testing (DST) [3–5]. SputumMicrobiol Infect 2015; 21: 1084–1092
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.08.024conversion is achieved in only 33–38% of retreatment cases in
such settings [5,6], which is a much lower rate than that ach-
ieved with DST-based treatments (38% vs. 79%) [5].
Liquid medium-based DST with automated culture systems
such as BACTEC 460 TB and BACTEC MGIT 960 [7] is efﬁ-
cient and fast, but expensive. Other disadvantages are invisible
contaminations, overgrowth of atypical mycobacteria, inability
to check the colony morphology and to determine the MIC,
and the need for multiple tubes or bottles [8]. GeneXpert, a
fast molecular-based test, was endorsed by the WHO for the
identiﬁcation of suspected MDR-TB cases [9]. However, the
high cost hampers its routine use in developing countries [9].
Moreover, the suspected MDR-TB cases detected by Gen-
eXpert still need to be conﬁrmed with a reference standard
technique [10], such as proportional DST on Löwenstein–
Jensen medium [11–13], which takes 6–8 weeks [14].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Nguyen et al. Microplate assay for M. tuberculosis DST 1085The proportional method on M7H10 agar developed by the
National Committee for Clinical Laboratory Standards is the
reference standard drug susceptibility test for mycobacteria in
the USA [15,16]. It is also used in The Netherlands and else-
where, but on microplates instead of in culture tubes or bottles,
providing a low-cost, high-throughput, fast and easy-to-read test
with high sensitivity, speciﬁcity, and reproducibility [8,17].
Recent studies have shown that some drug-resistant Mycobac-
terium tuberculosis isolates do not grow or grow very slowly on
M7H10 medium, leading to false drug-sensitive results. There-
fore, it was recommended to replace M7H10 with M7H11 agar,
which is supplemented with a pancreatic digest of casein, to
facilitate the growth of fastidiousM. tuberculosis cultures [18,19].
Here, we describe a proportional method for DST in 12-well
microplates with M7H11 medium supplemented with OADC
and low-magniﬁcation microscopic monitoring of bacterial
growth to reduce turn-around time. We compared the results
with those obtained with the conventional Canetti–Grosset
proportional method. We also sequenced the genes involved in
drug resistance to validate the DST proﬁles, and measured
MICs in M. tuberculosis isolates with conﬂicting DST and
sequencing results.Materials and methodsEthics statement
The National Institute of Hygiene and Epidemiology (NIHE)
ethics review committee, Vietnam, approved the study
protocol.
M. tuberculosis isolates
Two hundred and twelve M. tuberculosis isolates were randomly
selected at the National Lung Hospital (NLH) in Hanoi, which
has the highest rates of MDR-TB.
DST
The sensitivities of all M. tuberculosis isolates to the four drugs
used as ﬁrst-line TB treatment in Vietnam during the study
period (isoniazid, rifampicin, streptomycin, and ethambutol)
were tested with the Canetti–Grosset proportional technique,
as previously described [14], at the NHL, and also with the new
proportional microplate technique (described below) at the TB
Laboratory, NIHE, Vietnam. All experiments were performed
in biosafety level 3 laboratories. The critical inhibitory drug
concentrations (CIDCs) recommended by the WHO were
used (Table S1). Both methods determine the ‘growth pro-
portion’ of M. tuberculosis colonies in drug-containing medium
relative to that in drug-free medium, with the same inoculum.
An isolate was considered to be drug sensitive when no growthClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anor a growth proportion of <1% was observed, and drug
resistant when the growth proportion was 1%.
Preparation of DST microplates
The M7H11 agar (Difco, Maryland, USA) was prepared ac-
cording to the manufacturer’s instructions, and enriched with
10% OADC (Difco). Freshly prepared anti-TB drugs (Sigma;
INH: India, RMP, STM, EMB: China) at 100 × CIDC were added
(ﬁnal concentration of 1 × CIDC), or not added, to the agar,
which was then distributed at 3 mL/well in 12-well microplates
(Thermo Scientiﬁc Nunc), as described in Fig. S1. Plates were
labelled, kept at 4°C, and used within 1 month.
M. tuberculosis inoculation in DST microplates
Bacterial colonies from fresh cultures (4 weeks) were ho-
mogenized by vortexing in 15-mL Falcon tubes containing water
and glass beads. Larger particles were allowed to settle. The
supernatants were then transferred to new glass tubes, and
bacterial stock solutions (108 CFU/mL) were prepared with
McFarland standard No. 2 for adjustment. Bacterial solutions of
105 CFU/mL and 103 CFU/mL were prepared by making serial
ten-fold dilutions from the stock solutions in water. Fifty
microlitres of 105 CFU/mL bacterial solution was added to each
well of the DST microplate, except for control 2, where 50 μL
of 103 CFU/mL bacterial solution was inoculated. Three sides of
the microplate were sealed with tape, and plates were incu-
bated at 37°C in an incubator. Culture contamination and
M. tuberculosis growth were monitored by eye and under a
microscope at low resolution (10×) from day 1 to day 14, and
recorded on a follow-up form.
DST microplate reading
Results were read by naked eye or microscopy. The minimum
number of colonies in control 2 had to be at least ten for
interpretation of the assay. Isolates were considered to be
sensitive when, in drug-containing wells, no colonies or fewer
colonies than in control 2 were observed. Isolates were
considered to be resistant if the number of colonies in drug-
containing wells was higher than or equal to the number of
colonies in control 2 (Fig. 1).
Sequencing of drug resistance genes
PCR ampliﬁcation and DNA sequencing. The genetic elements of
resistance to rifampicin (a 1148-bp fragment in rpoB containing
the hotspot region), isoniazid (the entire sequences of katG and
inhA, and the inhA promoter), streptomycin (the entire se-
quences of rpsL and rrs) and ethambutol (a 1312-bp fragment in
embB containing the hotspot region) were PCR ampliﬁed and
sequenced. The primers and ampliﬁed regions are shown in
Table S2 [20–25]. The PCR conditions (with HotStarTag) wered Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1084–1092
FIG. 1. Reading of results in a 12-well microplate drug susceptibility testing assay. VNM7: Mycobacterium tuberculosis isolate resistant to isoniazid (INH)
(left half of the 12-well plate); VNM33: M. tuberculosis isolate resistant to INH, rifampicin (RMP), and streptomycin (SM) (right half of the 12-well plate).
Photograph taken at day 11 of culture.
1086 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIas follows: 15 min of Taq activation at 95°C, 35 cycles of 95°C
for 1 min, 58–62°C (Table S2) for 1.5 min, and 72°C for 2 min,
and 72°C for 5 min. PCR products were sequenced by Euroﬁns
MWG Operon or 1st BASE.
Sequence analysis
Each sequence was analysed with Bioedit and ClustalW soft-
wares. Point mutations were identiﬁed by comparison with the
sequence of the M. tuberculosis H37Rv reference strains in
GenBank (NC 000962).
Determination of rifampicin and ethambutol MICs
MICs were determined by use of the M7H11 microplate assay
with 0.031, 0.062, 0.124, 0.248, 0.496, 0.6, 0.7, 0.8, 0.9 and
1.0 mg/L rifampicin, and 2, 3, 4, 5, 6, 7 and 7.5 mg/L ethambutol.
The highest concentrations used for MIC testing were the
CIDCs recommended by the WHO.
Data analysis
Data were analysed with STATA 12 (Statacorp LP, TX, USA).
Sensitivity, speciﬁcity and Cohen’s kappa coefﬁcient with two-
sided 95% CIs were calculated for the proportional micro-
plate DST assay relative to the Canetti–Grosset method. AClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectkappa coefﬁcient of 0.81–0.99 was considered to indicate
almost perfect between-test agreement, and a kappa value of
1.0 was considered to indicate perfect agreement [26].ResultsAs four M. tuberculosis isolates were contaminated by fungi
during subculture and DST, only 208 isolates were analysed.
DST
DST results obtained with the Canetti–Grosset and the 12-well
microplate methods showed between-test discrepancies in only
eight M. tuberculosis isolates, with only one drug susceptibility
difference in most of the cases (Table S3 and 2 × 2 table in
Table S4). The sensitivity, speciﬁcity and kappa coefﬁcients for
detection of multidrug resistance and resistance to the four drugs
showed almost perfect agreement between methods (Table 1).
Time to results with the proportional microplate DST
assay
Visual growth monitoring of the ﬁrst 140 M. tuberculosis isolates
from day 1 to day 14 indicated that DST results could be read atious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1084–1092
TABLE 1. Sensitivity, speciﬁcity and kappa coefﬁcients for the
comparison of the proportional 12-well microplate and
Canetti–Grosset drug susceptibility testing assays
Drug
resistance
Sensitivity, %
(95% CI)
Speciﬁcity, %
(95% CI)
Kappa coefﬁcient
(± SE)
RMP 100 (94.5–100) 98.6 (95.0–99.8) 0.98 (0.91–1.00)
INH 99.0 (94.7–100) 99.0 (94.8–100) 0.98 (0.91–1.00)
SM 100 (96.8–100) 98.9 (94.2–100) 0.98 (0.91–1.00)
EMB 96.4 (81.7–99.9) 98.3 (95.2–99.7) 0.92 (0.85–0.99)
MDR 100 (93.8–100) 98.7 (95.3–99.8) 0.98 (0.91–1.00)
EMB, ethambutol; INH, isoniazid; MDR, multidrug resistant; RMP, rifampicin; SE,
standard error.
CMI Nguyen et al. Microplate assay for M. tuberculosis DST 1087days 5–6 for 108 isolates (77.1%) and at days 7–11 for the
remaining 32 isolates (22.9%). The mean time to results was 6.3
days. By microscopic observation (10×), DST results could be
read at days 4–5 for 115 isolates (82.1%) and at days 6–9 for 25
isolates (17.9%). The mean time to results was 4.7 days
(Table 2). Fig. 2 shows the microscopic follow-up of
M. tuberculosis growth in a control well from day 1 to day 12.
Sequencing of drug resistance genes
To validate the DST proﬁles, the main genes associated with
resistance to the four tested anti-TB drugs were sequenced in
the eight isolates with discordant DST results between tech-
niques and in 115 randomly selected isolates.
Overall, previously described drug resistance-associated
mutations were found at: codons 511, 516, 518, 522, 526,
531, 533 and 572 of rpoB (rifampicin resistance); at codon 315
of katG, at codon 21 of inhA, and at position –15 (C-T) of the
inhA promoter (isoniazid resistance); at codons 43 and 88 of
rpsL, and at positions 514, 517, 878, 1001 and 1401 of rrs
(streptomycin resistance); and at codons 306, 330, 354, 406
and 497 of embB (ethambutol resistance). Synonymous mu-
tations and mutations previously reported as not beingTABLE 2. Time to results when bacterial growth is monitored
in the proportional 12-well microplate drug susceptibility
testing assay by eye and under a low-magniﬁcation
microscope (140 Mycobacterium tuberculosis isolates)
Time (days)
No. of isolates (%)
By eye By microscopy
4 — 93 (66.4)
5 49 (35.0) 22 (15.7)
6 59 (42.1) 9 (6.4)
7 7 (5.0) 6 (4.3)
8 5 (3.6) 6 (4.3)
9 8 (5.7) 4 (2.9)
10 8 (5.7)
11 4 (2.9)
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anassociated with drug resistance were also identiﬁed (Table S5)
[24,25,27,28].
The frequencies of drug resistance-associated mutations
among the resistant and sensitive isolates identiﬁed with the
two DST assays are shown in Table 3. The level of agreement
between phenotypic susceptibility and genotypic determinants
was similar for the two techniques.
Gene sequencing of the eight isolates with discordant DST
results showed that, among these, both methods correctly
detected three of the six resistant isolates with mutations
(Table 4). For the ones without mutations, we did not consider
which assay results were more precise, because the known
molecular determinants targeted by sequencing cannot detect
100% of the drug resistant isolates.
Determination of the MICs for rifampicin and
ethambutol in isolates with phenotype–genotype
discrepancies
Because of the signiﬁcant number of isolates with phenotype–
genotype discrepancies concerning susceptibility to rifampicin
(seven of 74 isolates) and ethambutol (13 of 98 isolates), their
MICs for rifampicin and ethambutol were determined. In three
of the seven rifampicin-sensitive isolates with a rifampicin
resistance-associated mutation, and in all three control
rifampicin-sensitive isolates without detectable mutations, the
MIC for rifampicin was 0.248 mg/L. The other four rifampicin-
sensitive isolates with mutations had an MIC for rifampicin
between 0.6 mg/L and 0.9 mg/L (Table 5).
The MICs for ethambutol in 12 randomly selected
ethambutol-sensitive isolates without embB mutations (con-
trols) were 2 mg/L. Conversely, among the 13 ethambutol-
sensitive isolates with an ethambutol resistance-associated
mutation, 11 had an MIC for ethambutol of 6 mg/L, and two
had an MIC for ethambutol of 5 mg/L (Table 6).DiscussionSimpliﬁcation and time reduction for M. tuberculosis
DST with the proportional microplate assay
This proportional microplate assay is faster and simpler than
the currently used Canetti–Grosset method. Indeed, the
M7H11 medium promotes M. tuberculosis growth. Moreover,
microplates allow the microscopic detection of bacterial col-
onies before they can be seen with the naked eye, further
decreasing the time to results. Previous studies have shown
that M. tuberculosis can be detected on M7H11 from sputum
samples as early as 7 days [29–31]. A meta-analysis of the
results obtained with thin-layer agar and microscopic-
observation drug susceptibility assays, in which patients’d Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1084–1092
FIG. 2. Mycpbacterium tuberculosis growth on a control well of the 12-well microplate from day 1 to day 12 (control well: 105 CFU/mL bacterial
solution and no drug), monitored with a low-magniﬁcation (10×) microscope.
1088 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIspecimens are inoculated directly on drug-free and drug-
containing medium for DST, showed that the mean turn-
around times for the two assays were 11.1 days (95% CI
10.1–12.0) and 9.9 days (95% CI 4.1–15.8), respectively [32].
With our indirect proportional microplate assay and a low-
magniﬁcation microscope, primary results could be read at
day 4 (or day 6 with the naked eye) and the complete results
at day 9 (or day 11–12 by eye).TABLE 3. Frequency of mutations associated with resistance to a
Mycobacterium tuberculosis isolates characterized with each drug su
M. tuberculosis
Mutation frequency, no. (%)
Drug resistance (1) Canetti–Gros
Drug-resistant isolates RMP 44/46 (95.6)
INH 73/77 (94.8)
SM 62/70 (88.6)
EMB 22/24 (91.7)
Drug-sensitive isolates RMP 10/77 (13)
INH 2/46 (4.4)
SM 0/53 (0)
EMB 11/99 (11.1)
Columns (2), (3) and (4) shows the number of isolates with mutations that confer resistanc
resistant/sensitive to that drug (determined with each DST techniques and with both techni
EMB, ethambutol; INH, isoniazid; RMP, rifampicin; SM, streptomycin.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectA 12-well plate can be used to test four anti-TB drugs in two
M. tuberculosis isolates, whereas 12 culture tubes are needed for
testing the same number of drugs and isolates with the Can-
etti–Grosset technique. Therefore, inoculation, growth moni-
toring and result reading are much easier and less labour-
intensive and time-consuming. Moreover, the M7H11 medium
without fresh eggs is much simpler to prepare than Löw-
enstein– Jensen medium. On the basis of our experience, withntituberculosis drugs in the drug-resistant and drug-sensitive
sceptibility testing (DST) technique and with both techniques
set (2) Microplate DST (3) Both techniques (4)
47/49 (96) 44/46 (95.6)
73/77 (94.8) 73/76 (96)
62/71 (87.3) 62/70 (88.6)
20/22 (91) 19/21 (90.5)
7/74 (9.5) 7/74 (9.5)
2/46 (4.4) 2/45 (4.4)
0/52 (0) 0/52 (0)
13/101 (12.9) 14/10/98 (10.2)
e to the drug indicated in column (1) relative to the total number of isolates that are
ques); the corresponding mutation frequency is in parentheses.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1084–1092
TABLE 4. Mutations in genes involved in drug resistance found in the Mycobacterium tuberculosis isolates with discrepant drug
susceptibility testing results by the proportional Canetti–Grosset and 12-well microplate techniques
Isolates
Drug resistance proﬁle Drug resistance-associated mutations in the studied genes
Canetti–Grosset Microplate DST rpoB inhA/its promoter katG rpsL rrs embB
VNM48 RHSE RHS Asp526Val ND Ser315Thr Lys88Arg ND Met306Val
VNM53 Sensitive H ND ND ND ND ND ND
VNM56 HS RHS Leu533Pro ND Ser315Thr Lys88Arg ND ND
VNM151 H RH Leu533Pro ND Ser315Thr ND ND Gln497Arg
VNM152 H Sensitive ND ND ND ND ND ND
VNM165 RH RHSE Ser531Leu ND Ser315Thr ND ND Asp354Ala
VNM180 HE H Leu533Pro ND Ser315Thr ND ND Met306Val
VNM182 HE H ND ND Ser315Thr ND ND Met306Val
E, ethambutol; H, isoniazid; R, rifampicin; S, streptomycin; ND, not detected.
CMI Nguyen et al. Microplate assay for M. tuberculosis DST 1089the same amount of time and labour, the number of tests
performed can be increased by at least four-fold.
Validation of proportional microplate DST for M.
tuberculosis
For detection of multidrug resistance and resistance to
isoniazid, rifampicin, and streptomycin, the sensitivity of
proportional microplate DST ranged between 99.0% (95% CI
94.7–100%) and 100.0% (95% CI 96.8–100%) and the
speciﬁcity ranged between 98.6% (95% CI 95.0–99.8%) and
99.0% (95% CI 94.8–100%), as compared with the propor-
tional Canetti–Grosset technique. Similarly, the kappa co-
efﬁcients between tests was 0.98 (95% CI 0.91–1.00),
indicating almost perfect agreement between the techniques.
Previous studies also showed that all assessments of rifam-
picin and isoniazid resistance with the thin-layer agar assays
yielded 100% accuracy, showing a promising diagnostic
technique. However, the WHO expert group agreed that
more evidence is needed before the use of these assays can
be recommended [32].
For ethambutol, the speciﬁcity was as high as for the other
drugs (98.3%; 95% CI 95.2–99.7%), whereas the sensitivity wasTABLE 5. Measurement by microplate assay of the MIC for rifampic
harbour rifampicin resistance-associated mutation(s) in rpoB
No. Isolate
RMP susceptibility
Canetti–Grosset Microplate assay
1 VNM148 S S
2 VNM162 S S
3 VNM168 S S
4 VNM192 S S
5 VNM193 S S
6 VNM194 S S
7 VNM208 S S
8 VNM137 S S
9 VNM166 S S
10 VNM182 S S
ND, not detected; S, sensitive.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anlower (96.4%; 95% CI 81.7–99.9%), and consequently also the
kappa index was lower (0.92; 95% CI 0.83–0.97). DST results
for ethambutol are frequently less reproducible [33]. Thus, a
lower kappa index does not mean that the microplate assay is
less precise than the Canetti–Grosset technique. Ängeby et al.
showed that the low reproducibility for ethambutol is due to
the use of non-optimal critical drug concentrations that cannot
discriminate between wild-type and drug-resistant isolates
[33].
Sequencing showed similar phenotype–genotype agreement
for the two techniques. This suggests that the precision of the
proportional microplate assay is comparable to that of the
proportional Canetti–Grosset technique.
The need for adjustment of the critical concentration
for ethambutol susceptibility testing
On the basis of the WHO recommended critical concentra-
tions, we missed 11 (33%) and 13 (39%) ethambutol-resistant
mutants with the Canetti–Grosset technique and the micro-
plate assay, respectively. All of the missed isolates had signiﬁ-
cantly higher MICs than those of the non-mutants (5–6 mg/L vs.
2 mg/L). These data strongly suggest that the criticalin (RMP) in rifampicin-sensitive isolates that harbour or do not
RMP resistance-associated mutation(s) in rpoB MIC (mg/L)
Leu511Pro 0.248
Leu533Pro 0.248
Leu533Pro 0.6
Asp516Tyr 0.248
Leu511Pro 0.7
Leu533Pro 0.7
Leu533Pro 0.9
ND 0.248
ND 0.248
ND 0.248
d Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1084–1092
TABLE 6. Measurement by microplate assay of the MIC for ethambutol (EMB, China) in ethambutol-sensitive isolates harbouring
or not harbouring ethambutol resistance-associated mutation(s) in embB
No. Isolate
EMB susceptibility
EMB resistance-associated mutation(s) in embB MIC (mg/L)Canetti–Grosset Microplate assay
1 VNM32 S S Gln497Arg 6.0
2 VNM69 S S Gln497Arg 6.0
3 VNM57 S S Met306Ile 6.0
4 VNM72 S S Met306Ile 6.0
5 VNM76 S S Met306Ile 6.0
6 VNM163 S S Gln497Arg 5.0
7 VNM164 S S Phe330Leu 6.0
8 VNM179 S S Gly406Asp 5.0
9 VNM188 S S Gly406Asp 6.0
10 VNM151 S S Gln497Arg 6.0
11 VNM48 R S Met306Val 6.0
12 VNM180 R S Met306Val 6.0
13 VNM182 R S Met306Val 6.0
14 VNM137 S S ND 2.0
15 VNM138 S S ND 2.0
16 VNM152 S S ND 2.0
17 VNM153 S S ND 2.0
18 VNM51 S S ND 2.0
19 VNM36 S S ND 2.0
20 VNM107 S S ND 2.0
21 VNM178 S S ND 2.0
22 VNM56 S S ND 2.0
23 VNM85 S S ND 2.0
24 VNM185 S S ND 2.0
25 VNM96 S S ND 2.0
ND, not detected; R, resistant; S, sensitive.
1090 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIethambutol concentration should be revised, especially because
the currently used cut-offs are not based on clinical evidence
[33].
Rifampicin-sensitive isolates carrying rifampicin
resistance-associated mutations
All of the isolates that carried rifampicin resistance-associated
mutations but were phenotypically rifampicin-sensitive had
MICs lower than the critical concentration recommended by
the WHO. Three of them had MICs as low as those of the non-
mutants (0.248 mg/L). This suggests that, for these isolates,
molecular-based DST could lead to false-positive results. A
recent study also indicated that not only the presence but also
the nature of rpoB mutations must be assessed for accurate
diagnosis of rifampicin resistance in M. tuberculosis [34]. More-
over, all of the mutations found in susceptible isolates in our
study have been previously reported to be associated with low
rifampicin resistance [27,35–39]. This observation supports the
need to re-evaluate the current molecular-based DST assays.ConclusionsOur proportional microplate assay for M. tuberculosis DST is as
accurate as the proportional Canetti–Grosset technique, but
easier to perform. It can provide DST results as rapidly as
automated liquid culture systems [7], but is much more
affordable. It also allows calculation of the growth proportionClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectand observation of the colony morphology, thus reducing the
contamination problems of liquid cultures. Therefore, it could
facilitate the diagnosis of drug-resistant TB in developing
countries for better control of drug-resistant TB. However, the
critical ethambutol concentration may need to be adjusted to
improve the precision of ethambutol susceptibility testing.Transparency declarationThe authors declare no conﬂicts of interest.AcknowledgementsWe would like to thank the NLH of Vietnam for M. tuberculosis
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